Published in Radiology on May 16, 2007
Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev (2010) 2.44
Photodynamic therapy for prostate cancer--a review of current status and future promise. Nat Clin Pract Urol (2009) 1.62
Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics (2012) 1.30
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res (2008) 1.26
High-field magnetic resonance imaging of the response of human prostate cancer to Pc 4-based photodynamic therapy in an animal model. Lasers Surg Med (2007) 1.26
Multidisciplinary functional MR imaging for prostate cancer. Korean J Radiol (2009) 1.04
Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol (2010) 1.00
Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy. J Magn Reson Imaging (2010) 0.95
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int (2013) 0.94
Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights Imaging (2015) 0.91
Photodynamic therapy for focal ablation of the prostate. World J Urol (2010) 0.88
Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. Br J Cancer (2009) 0.86
Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol (2008) 0.85
Combination of photodynamic therapy and immunomodulation: current status and future trends. Med Res Rev (2008) 0.85
Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J (2009) 0.84
Robotic image-guided needle interventions of the prostate. Rev Urol (2009) 0.81
Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy. Can Urol Assoc J (2014) 0.80
CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. Phys Med Biol (2014) 0.78
Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment. Cancer Imaging (2011) 0.78
Advancements in magnetic resonance-guided robotic interventions in the prostate. Top Magn Reson Imaging (2008) 0.78
Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight. World J Methodol (2016) 0.75
Magnetic Resonance Imaging of the Prostate, Including Pre- and Postinterventions. Semin Intervent Radiol (2016) 0.75
Post-treatment MRI aspects of photodynamic therapy for prostate cancer. Insights Imaging (2014) 0.75
Quantitative Multi-Parametric Magnetic Resonance Imaging of Tumor Response to Photodynamic Therapy. PLoS One (2016) 0.75
Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning. Lasers Med Sci (2017) 0.75
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2010) 6.01
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Speckle variance detection of microvasculature using swept-source optical coherence tomography. Opt Lett (2008) 5.38
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Validating whole slide imaging for diagnostic purposes in pathology: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med (2013) 3.39
Review of the current state of whole slide imaging in pathology. J Pathol Inform (2011) 3.23
Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg (2011) 2.86
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2013) 2.53
The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol (2002) 2.48
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. J Urol (2012) 2.42
Optimized speckle variance OCT imaging of microvasculature. Opt Lett (2010) 2.36
Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol (2007) 2.33
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet (2006) 2.23
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas. Neurosurg Focus (2011) 2.22
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
The use of a novel reverse thermosensitive polymer to prevent ureteral stone retropulsion during intracorporeal lithotripsy: a randomized, controlled trial. J Urol (2010) 2.20
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst (2012) 2.06
The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement. Eur Urol (2007) 2.03
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis (2005) 1.93
uPM3, a new molecular urine test for the detection of prostate cancer. Urology (2004) 1.91
Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem Photobiol (2002) 1.90
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
Quantification of in vivo fluorescence decoupled from the effects of tissue optical properties using fiber-optic spectroscopy measurements. J Biomed Opt (2011) 1.83
Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc Natl Acad Sci U S A (2012) 1.80
Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol (2009) 1.77
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res (2007) 1.75
Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol (2007) 1.72
A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol (2006) 1.71
Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol (2003) 1.70
Endoscopic Doppler optical coherence tomography in the human GI tract: initial experience. Gastrointest Endosc (2005) 1.68
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66
Training future surgeons for management roles: the resident-surgeon-manager conference. Arch Surg (2012) 1.60
Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology (2007) 1.58
Current status of local salvage therapies following radiation failure for prostate cancer. J Urol (2005) 1.57
Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol (2010) 1.57
Population based survival data on urachal tumors. J Urol (2006) 1.55
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54
Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol (2008) 1.53
Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int (2006) 1.53
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int (2009) 1.48
Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther (2007) 1.48
Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. Eur J Cancer (2008) 1.48
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47
The microenvironment effect on the generation of reactive oxygen species by Pd-bacteriopheophorbide. J Am Chem Soc (2005) 1.47
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
Physical activity and quality of life after radical prostatectomy. Can Urol Assoc J (2010) 1.44
Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: current status, challenges and future prospects. Photochem Photobiol (2007) 1.43
A fiberoptic reflectance probe with multiple source-collector separations to increase the dynamic range of derived tissue optical absorption and scattering coefficients. Opt Express (2010) 1.41
Radical prostatectomy in obese patients: Improved surgical outcomes in recent years. Int J Urol (2010) 1.41
Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer? BJU Int (2005) 1.41
Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res (2012) 1.41
Ghrelin receptor as a novel imaging target for prostatic neoplasms. Prostate (2011) 1.40
Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res (2009) 1.39
Personal digital assistant data capture: the future of quality of life measurement in prostate cancer treatment. J Oncol Pract (2007) 1.39
Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol (2009) 1.39
Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci U S A (2007) 1.38
Nonlinear optical properties of type I collagen fibers studied by polarization dependent second harmonic generation microscopy. J Phys Chem B (2011) 1.38
Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology (2010) 1.36
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol (2007) 1.34